ERBB2 and neoplasm: Trastuzumab is a Her-2 monoclonal antibody that inhibits the growth of Her-2-positive tumor cells by inhibiting the interaction between growth factors and tumor cells and has significant clinical efficacy (Kulhari et al., 2015).